Edition:
India

Roche Holding AG (RHHBY.PK)

RHHBY.PK on OTC Markets Group

41.22USD
23 Nov 2020
Change (% chg)

$-0.46 (-1.09%)
Prev Close
$41.68
Open
$41.79
Day's High
$41.83
Day's Low
$41.16
Volume
1,491,871
Avg. Vol
1,070,447
52-wk High
$47.15
52-wk Low
$35.04

Latest Key Developments (Source: Significant Developments)

Roche Says CHMP Recommends EU Approval Of Phesgo For Her2-Positive Breast Cancer
Friday, 13 Nov 2020 

Nov 13 (Reuters) - Roche Holding AG ::CHMP RECOMMENDS EU APPROVAL OF ROCHE'S PHESGO (FIXED-DOSE COMBINATION OF PERJETA AND HERCEPTIN FOR SUBCUTANEOUS INJECTION) FOR HER2-POSITIVE BREAST CANCER.PHESGO OFFERS FASTER AND LESS INVASIVE DELIVERY OF STANDARD OF CARE TREATMENT WITH PERJETA AND HERCEPTIN, UNDER SKIN IN JUST MINUTES, COMPARED TO HOURS WITH INTRAVENOUS INFUSION.SUBCUTANEOUS ADMINISTRATION IS PREFERRED BY PATIENTS, PHYSICIANS AND HEALTHCARE PROVIDERS, AND CAN BE ASSOCIATED WITH REDUCED HOSPITAL TIMES AND COSTS.THIS IS FIRST TIME THAT ROCHE HAS COMBINED TWO MONOCLONAL ANTIBODIES THAT CAN BE ADMINISTERED BY A SINGLE SUBCUTANEOUS INJECTION.  Full Article

EMA Says CHMP Recommends Granting Marketing Authorisation For Phesgo To Treat A Form of Breast Cancer
Friday, 13 Nov 2020 

Nov 13 (Reuters) - EMA::EMA - CHMP RECOMMENDED GRANTING MARKETING AUTHORISATION FOR PHESGO FOR TREATMENT OF EARLY AND METASTATIC BREAST CANCER.EMA - XOFLUZA (BALOXAVIR MARBOXIL) RECEIVED POSITIVE OPINION FROM CHMP FOR TREATMENT AND POST-EXPOSURE PROPHYLAXIS OF UNCOMPLICATED INFLUENZA.  Full Article

Dyno Therapeutics Enters Collaboration And License Agreement With Roche
Wednesday, 14 Oct 2020 

Oct 14 (Reuters) - Roche Holding AG ::DYNO THERAPEUTICS ENTERS COLLABORATION AND LICENSE AGREEMENT WITH ROCHE TO DEVELOP NEXT-GENERATION AAV GENE THERAPY VECTORS FOR CNS DISEASES AND LIVER-DIRECTED THERAPIES.DYNO THERAPEUTICS - DYNO IS ELIGIBLE TO RECEIVE MILESTONE PAYMENTS THAT MAY EXCEED $1.8 BILLION.DYNO THERAPEUTICS - WILL RECEIVE AN UNDISCLOSED UPFRONT PAYMENT AND IF SUCCESSFUL, IS ELIGIBLE TO RECEIVE ADDITIONAL PAYMENTS.  Full Article

Quest Diagnostics Launches Three New Combined Covid-19 And Respiratory Virus Tests
Wednesday, 30 Sep 2020 

Sept 30 (Reuters) - Quest Diagnostics Inc ::QUEST DIAGNOSTICS LAUNCHES THREE NEW COMBINED COVID-19 AND RESPIRATORY VIRUS TESTS.QUEST DIAGNOSTICS - HEALTHCARE PROVIDERS ACROSS U.S. CAN NOW ACCESS 3 DIFFERENT TEST OPTIONS FROM QUEST DIAGNOSTICS TO AID DIAGNOSIS OF COVID-19.QUEST DIAGNOSTICS - NEW TEST OPTIONS INCLUDE COBAS SARS-COV-2 & INFLUENZA A/B*, AUTOMATED HIGH THROUGHPUT MULTIPLEX REAL-TIME RT-PCR ASSAY FROM ROCHE.QUEST DIAGNOSTICS INC - EACH RESPIRATORY PANEL TEST ALSO ONLY REQUIRES A SINGLE NASOPHARYNGEAL SPECIMEN.  Full Article

AC Immune Reports Top Line Results From Tauriel Phase 2 Trial Evaluating Semorinemab In Early Alzheimer’s Disease
Wednesday, 23 Sep 2020 

Sept 23 (Reuters) - AC Immune SA ::AC IMMUNE REPORTS TOP LINE RESULTS FROM TAURIEL PHASE 2 TRIAL EVALUATING SEMORINEMAB IN EARLY ALZHEIMER’S DISEASE.AC IMMUNE SA - GENENTECH DISCLOSED ANTI-TAU ANTIBODY DID NOT MEET THE CO-PRIMARY EFFICACY ENDPOINT OR TWO SECONDARY ENDPOINTS IN THE TAURIEL STUDY.AC IMMUNE SA - INVESTIGATIONAL NEW DRUG (IND) ENABLING STUDIES ONGOING FOR FIRST-IN-CLASS THERAPEUTIC CANDIDATES TARGETING TDP-43 AND ALPHA-SYNUCLEIN.AC IMMUNE SA - GENENTECH, INFORMED CO OF STUDY RESULTS WHICH SHOW THAT SEMORINEMAB DID NOT MEET ITS PRIMARY EFFICACY ENDPOINT.AC IMMUNE SA - AC IMMUNE REMAINS IN A STRONG FINANCIAL POSITION WITH OPERATIONS FULLY FINANCED THROUGH Q1 2024.  Full Article

Inflazome Announces Acquisition By Roche
Monday, 21 Sep 2020 

Sept 21 (Reuters) - Inflazome::INFLAZOME ANNOUNCES ACQUISITION BY ROCHE.ACQUISITION OF INFLAZOME GIVES ROCHE FULL RIGHTS TO INFLAZOME PORTFOLIO.INFLAZOME SHAREHOLDERS RECEIVED EUR 380 MILLION UPFRONT, AND ARE ELIGIBLE TO RECEIVE ADDITIONAL MILESTONE PAYMENTS.  Full Article

Roche Presents New Data From Multiple Phase III Studies Of Tecentriq In Triple-Negative Breast Cancer
Saturday, 19 Sep 2020 

Sept 19 (Reuters) - Roche Holding AG ::ROCHE PRESENTS NEW DATA FROM MULTIPLE PHASE III STUDIES OF TECENTRIQ IN TRIPLE-NEGATIVE BREAST CANCER AT ESMO VIRTUAL CONGRESS 2020.ROCHE - FINAL OVERALL SURVIVAL DATA FROM PHASE III IMPASSION130 STUDY WERE CONSISTENT WITH PRIOR INTERIM ANALYSES IN PATIENTS WITH METASTATIC TNBC.RESULTS FROM THE PHASE III IMPASSION131 STUDY DID NOT MEET ITS PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL.  Full Article

Roche Launches New Quantitative Antibody Test To Measure Sars-Cov-2 Antibodies
Friday, 18 Sep 2020 

Sept 18 (Reuters) - Roche Holding AG ::ROCHE LAUNCHES NEW QUANTITATIVE ANTIBODY TEST TO MEASURE SARS-COV-2 ANTIBODIES, TO SUPPORT EVALUATION OF VACCINES.NEW ELECSYS ANTI-SARS-COV-2 S TEST CAN QUANTITATIVELY MEASURE LEVEL OF ANTIBODIES AGAINST SARS-COV-2 IN PATIENTS WHO HAVE BEEN EXPOSED TO VIRUS.TEST TARGETS ANTIBODIES AGAINST SPIKE PROTEIN. THIS IS FOCUS OF VACCINES IN DEVELOPMENT AND CONVALESCENT PLASMA THERAPY..USING ELECSYS ANTI-SARS-COV-2 S ANTIBODY TEST, TOGETHER WITH ELECSYS ANTI-SARS-COV-2* TEST LAUNCHED IN MAY, CAN HELP TO MORE EFFECTIVELY DETERMINE PERCENTAGE OF A POPULATION WHO ALREADY HAVE ANTIBODIES AGAINST SARS-COV-2.  Full Article

Roche Says Actemra/Roactemra Reduce Mechanical Ventilation Risk In COVID-19 Patients
Friday, 18 Sep 2020 

Sept 18 (Reuters) - Roche Holding AG ::ROCHE’S PHASE III EMPACTA STUDY SHOWED ACTEMRA/ROACTEMRA REDUCED THE LIKELIHOOD OF NEEDING MECHANICAL VENTILATION IN HOSPITALISED PATIENTS WITH COVID-19 ASSOCIATED PNEUMONIA.EMPACTA IS FIRST GLOBAL PHASE III TRIAL TO SHOW EFFICACY WITH ACTEMRA/ROACTEMRA IN COVID-19 ASSOCIATED PNEUMONIA AND FIRST WITH A FOCUS ON ENROLLING LARGELY UNDERSERVED AND MINORITY PATIENTS.NO STATISTICAL DIFFERENCE IN MORTALITY BETWEEN PATIENTS WHO RECEIVED ACTEMRA/ROACTEMRA OR PLACEBO.ROCHE PLANS TO SHARE THESE RESULTS WITH HEALTH AUTHORITIES, INCLUDING US FDA.EMPACTA STUDY DID NOT IDENTIFY ANY NEW SAFETY SIGNALS FOR ACTEMRA/ROACTEMRA.  Full Article

Roche Says New Data Further Shows Ocrevus’ Effectiveness
Friday, 11 Sep 2020 

Sept 11 (Reuters) - Roche Holding AG ::NEW DATA FURTHER REINFORCE ROCHE’S OCREVUS (OCRELIZUMAB) AS A HIGHLY EFFECTIVE TREATMENT FOR PEOPLE WITH MULTIPLE SCLEROSIS.NEW DATA SHOW OCREVUS® (OCRELIZUMAB) IS A HIGHLY EFFECTIVE TREATMENT OPTION FOR PEOPLE WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) WHO EXPERIENCED A SUBOPTIMAL RESPONSE TO THEIR PRIOR DISEASE MODIFYING THERAPY (DMT).75% OF PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) AND SUBOPTIMAL RESPONSE TO PRIOR TREATMENT HAD NO EVIDENCE OF DISEASE ACTIVITY TWO YEARS AFTER SWITCHING TO OCREVUS IN OPEN-LABEL PHASE IIIB CASTING STUDY.OCREVUS IS FIRST AND ONLY TREATMENT APPROVED FOR BOTH RELAPSING MS (RMS) AND PRIMARY PROGRESSIVE MS (PPMS).MORE THAN 170,000 PEOPLE HAVE BEEN TREATED WITH OCREVUS GLOBALLY IN CLINICAL TRIAL AND REAL-WORLD SETTINGS.  Full Article

Photo

Roche, Atea team up on potential COVID-19 pill

ZURICH Roche Holding and Atea Pharmaceuticals have joined forces to develop an antiviral oral treatment called AT-527, now in phase 2 clinical trials, as a potential treatment for COVID-19 patients, the companies said on Thursday.

No consensus analysis data available.